The Medicare GLP-1 Effect: How Coverage Expansion Is Rewriting Pharma Media Strategy The expansion of Medicare coverage for GLP-1 therapies represents one of the biggest shifts in healthcare marketing and pharmaceutical commercialization in recent years
Ese es el salto relevante del reclamo GLP-1 friendly en los alimentos, que est haciendo furor en Estados Unidos
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist
l , Baseline rectal temperature on day 7
While GLP-1 therapy may occasionally cause minor digestive discomfort, such as temporary nausea or mild gastrointestinal effects, these symptoms typically fade as your body adjusts to the treatment
As a result, the absence of increased cancer incidence in short-to mid-term follow-up cannot be equated with long-term oncological safety